Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy – EurekAlert (press release)
EurekAlert (press release) |
Preclinical MD Anderson study suggests ARID1a may be useful biomarker for immunotherapy
EurekAlert (press release) The preclinical study suggests that mutations in ARID1a could be beneficial in predicting immunotherapy success. The findings, published today in Nature Medicine, are the first to identify a role for ARID1a in regulating mismatch repair (MMR), a normal … |
